|
Name of drug |
Dosage forms and Strengths |
Level |
|
1.0 Anasthetics, Preoperative Medicines and Medical Gases |
||
|
1.1 General Anaesthetics and Oxygen |
||
|
1.1.1 Inhalational Medicines |
||
|
Halothane |
Liquid for inhalation, bottle 250mL |
B |
|
Isoflurane |
Liquid for inhalation, 250MmL |
B |
|
Nitrous oxide |
Cylinder (F gas) for inhalation |
C |
|
Oxygen |
Cylinder (medical gas) for inhalation |
B |
|
Sevoflurane |
Inhalation |
S |
|
1.1.2 Injectable Medicines and Other Pre-Medication |
||
|
Atropine |
Injection 1mg (as sulfate in 1mL ampoule) |
A |
|
Calcium chloride |
Injection 10mcg/mL |
D |
|
Clonidine |
Injection 500mcg/mL |
S |
|
Dexmedetomidine |
Injection 100mcg/mL |
S |
|
Ephedrine injection |
Injection 30mg/mL |
B |
|
Flumazenil |
Injection 0.2mg (IV) |
A |
|
Etomidate |
Injection 20mg/mL |
S |
|
Glycopyrrolate |
Injection 200mcg/mL in 1mL, 600mcg in 3mL |
S |
|
Ketamine |
Injection (hydrochloride), 10mg/mL in 20mL |
B |
|
Labetalol |
Injection 10mg/mL |
C |
|
Lipid emulsion |
Solution 20% |
S |
|
Metaraminol |
Injection 1mg/mL |
S |
|
Midazolam |
Injection 1mg/mL, 5mg/mL |
D |
|
Noradrenaline |
Injection 2mg/mL |
S |
|
Ondansetron |
Injection 2mg/mL |
S |
|
Phenylephrine |
Injection 10mg/mL |
S |
|
Propofol |
Injection 10mg/mL, 20mg/mL |
D |
|
Sodium citrate |
Solution 0.3 moles |
D |
|
Thiopental |
Injection (sodium salt), in 20mL |
C |
|
1.2 Local Anaesthetics |
||
|
Bupivacaine |
Injection 0.5% (hydrochloride) in 7.5% dextrose spinal |
C |
|
Bupivacaine |
C |
|
|
Lidocaine |
Injection hydrochloride 1% & 2%; |
A |
|
Lidocaine |
Gel 2% & 5%; Spray 10% |
B |
|
Lidocaine in Dextrose |
Injection (hydrochloride), 5% in 7.5% dextrose |
B |
|
Lidoocaine + epinephrine (adrenaline) |
Injection (hydrochloride) 2% with adrenaline 1:100,000 in 2mL ampoule for dental use |
A |
|
1.3 Muscle Relaxants and Cholinesterase Inhibitors |
||
|
Atracurium |
Injection 50mg/5mL |
S |
|
Baclofen |
Tablet 10mg |
S |
|
Neostigmine |
Injection (hydrochloride or hydrogen tartarate),1mg/mL in 1mL ampoule Injection (hydrochloride or hydrogen tartarate), 2.5mg/mL in 1mL ampoule |
B |
|
Pancuronium |
Injection (bromide) 4mg/mL in 2mL ampoule |
C |
|
Rocuronium |
Injection 50mg/5mL |
S |
|
Sugammadex |
Injection: 100mg/mL |
S |
|
Suxamethonium |
Powder for injection (bromide or chloride) 50mg/mL in 2mL vial |
C |
|
Tizanidine |
Tablet/Capsule:2mg; 4mg |
S |
The National Essential Medicines List (NEMLIT)
exp date isn't null, but text field is
Background Information
The National Essential Medicines List (NEMLIT) presents essential medicines, for which health facilities at all levels requisite for management of priority diseases. The NEMLIT is based on the concept of essential medicines, defined by the World Health Organization (WHO) as those medicines that meet priority healthcare needs of the population and intended to be available within the context of functioning health systems at all times, with assured quality and at a price the individual and the community can afford. The concept emphasizes carefully and systematically selection of essential medicines using an evidence-based process with due consideration of clear evidence of safety and efficacy and comparative cost effectiveness. The rationale for selecting a limited number of essential medicines is to enhance supply, improve rational use, and lower costs.
Categorization of antibiotics
A new categorization of antibiotics into Access, Watch, Reserve (AWaRe) classification has been introduced to guide their prudent use and reduce antimicrobial resistance.
Access Group Antibiotics
This group includes antibiotics that have activity against a wide range of commonly encountered susceptible pathogens while also showing lower resistance potential than antibiotics in the other groups. Access group antibiotics are recommended as essential first or second choice empiric treatment options for infectious syndromes. They are essential antibiotics that should be widely available, affordable and quality assured.
Watch Group Antibiotics
This group includes antibiotic classes that have higher resistance potential. These medicines should be prioritized as key targets of stewardship programs and monitoring. The selected Watch group antibiotics are recommended as essential first or second choice empiric treatment options for a limited number of specific infectious syndromes.
Reserve Group Antibiotics
This group includes antibiotics that should be reserved for treatment of confirmed or suspected infections due to multi-drug-resistant organisms. Reserve group antibiotics should be treated as “last resort” options. While they must be accessible when required, their use should be limited to highly specific patients and clinical settings, when other antibiotic alternatives have failed or are not suitable. They should be protected and prioritized as key targets of national and international AMR stewardship programmes, involving monitoring and utilization reporting, to preserve their effectiveness.
Prescribing of Medicines with Regard to Level of Service Provision and Professional Expertise
Similar to previous editions, the NEMLIT will be used with regard to levels of care. Additionally, a new categorization of prescribing medicines with regards to expertise has been introduced to facilitate reimbursement of medicines by the NHIF. In summary, stocking and prescribing of medicines as per level of care will be: tertiary hospitals (A, B, C, D & S); Regional Referral Hospitals (A, B, C & D); District Hospitals (A, B & C); Health Centers (A & B) and dispensaries (A). Additional category reflects professional expertise; regardless of level of care: Specialists (A, B, C, D & S); Medical Officers (A, B, C & D); Assistant Medical Officer (A, B & C); Clinical Officers (A & B) and Assistant Clinical Officers (A).
Table 1: Restrictions for Prescribing Medicines Listed in the NEMLIT
| Level of Medicines with Regard to Service Provision | Level of Medicines with Regard to Professional Expertise | ||
| Tertiary Hospital | A,B,C,D,S | Specialist | A,B,C,D,S |
| Regional Referral Hospital | A,B,C,D | Medical Officer (MO) | A,B,C,D |
| District Hospital | A,B,C | Assistant Medical Officer (AMO) | A,B,C |
| Health Centre | A & B | Clinical Officer (CO) | A & B |
| Dispensary | A | Assistant Clinical Officer (ACO) | A |
Hence, at tertiary level hospitals (S); the National, Zonal Referral and Specialized hospitals, all medicines in the NEMLIT may be stocked; as per hospital needs and specialists may prescribe all medicines listed in the NEMLIT. However, level (S) medicines are restricted to other experts. Implying that, a Medical Officers at tertiary hospital will be prescribe medicines listed A, B, C and D and Assistant Medical Officer A, B, & C but not S.
At Regional Referral Hospitals (RRH) level, medicines listed as (A, B, C & D) will be stocked. Specialists at that level may prescribe medicines at level (A, B, C, D, S) as per their specialty areas e.g. cardiologist may prescribe cardiovascular diseases medicines at that level. Medical officer at RRH will prescribe medicines at level (A, B, C, D). If there is an Assistant Medical Officer at RRH allowed to prescribe medicines listed (A, B, C) and Clinical Officers (A & B).
At District hospitals level, medicines listed as (A, B & C) will be stocked. Specialists prescribe medicines listed (A, B, C, D, S) as above. Medical Officers will prescribe medicines listed (A, B, C, D) and AMO (A, B, C). If their Clinical Officers (CO) at that level will be permitted to prescribe medicines listed A & B only. Health Centers stock medicines listed as A & B and dispensaries A, but if there is AMO, MO or specialist will prescribe as above.
Note
- Different from previous editions, the arrangement of STG/NEMLIT have changed; the NEMLIT starts followed by chapters of STG to make easy reference of essential medicines by users.
- All medicines indicated for treatment of various diseases in the STG are listed in the NEMLIT.
- Some medicines are listed in some levels for the treatment of specific disease condition e.g. cefixime is level (D) but, may be prescribed in lower HFs for treatment of STI only.
- Medicines in the NEMLIT are grouped according to pharmacological groups and written alphabetically, in generic names, with their dosage forms and strengths.
- All health facilities in the public sector will adhere to the NEMLIT in procurement of medicines from MSD and other sources.
- The NHIF will adhere to the NEMLIT for reimbursement of medicines in both public and private health facilities.
- Special arrangement to quantify and procure medicines, which are not managed at specific health facilities but are needed due to presence of expertise as stated above; for that case the Hospital Pharmacists in collaboration with the Office of Chief Pharmacist shall facilitate the process.
Further recommendations, advices and clarifications of the use of this document are much welcome; please, you may communicate with the office of the Director Pharmaceutical Services - Ministry of Health, Community Development, Gender, Elderly and Children. We believe that all medicines stocked in our health facilities are of assured quality. However, for recommendations and advices concerning all aspects of the quality of medicines and any adverse reaction please contact the Tanzania Medicines and Medical Devices Authority at www.tmda.go.tz .
|
Name of drug |
Dosage forms and Strengths |
Level |
|
2.1 Non-opioids and Non-steroidal Anti-inflammatory Medicines (NSAIMs) |
||
|
Acetylsalicylic acid |
Tablet 300mg |
A |
|
Dexketoprofen |
Tablet 25mg |
S |
|
Diclofenac |
Injection 25mg/mL; Recto caps 100mg (slow release); Gel. |
A |
|
Diclofenac |
Tablet (sodium/potassium salt) 50mg, 100mg; |
C |
|
Ketoprofen |
Tablet/Capsule: 50mg, 75mg, 200mg; Gel 2.5% w/w |
S |
|
Ibuprofen |
Tablet 200mg; 400mg ; Syrup 100mg/5ml |
A |
|
Mefenamic Acid |
Tablet 500mg |
B |
|
Meloxicam |
Tablet 7.5mg; 15mg |
D |
|
Paracetamol |
Tablet 500mg; Syrup 125mg/5mL, suppositories 125mg |
A |
|
10 mg/mL Solution for Infusion |
D |
|
|
Piroxicam |
Tablet 20mg |
A |
|
Sulfasalazine |
Tablets 500mg |
D |
|
2.2 Opioid Analgesics/Antagonists |
||
|
Fentanyl |
Injection 100mcg/2mL; Patches |
S |
|
Methadone |
Tablet: 5mg; 10mg (as hydrochloride); Oral liquid: 5mg/5mL; 10mg/5mL (as hydrochloride); Concentrate for oral liquid: 5mg/mL; 10mg/mL (as hydrochloride) |
C |
|
Morphine |
Tablet 10mg (morphine hydrochloride or morphine sulfate); Granules (slow-release: to mix with water) 20mg-200mg (morphine sulfate); Oral liquid: (10mg morphine hydrochloride or morphine sulfate)/5mL; Injection:10mg (morphine hydrochloride or morphine sulfate) in 1mL ampoule |
C |
|
Naloxone |
Injection (hydrochloride) 0.4mg/mL in 1mL ampoule |
B |
|
Pethidine |
Injection (hydrochloride) 50mg/mL in 1mL and 2mL ampoule |
B |
|
Tramadol |
Tablet 50mg; Injection 50mg/mL in 2mL |
B |
|
2.3 Medicines for Other Common Symptoms in Palliative Care |
||
|
Amitriptyline |
Tablet 25mg |
A |
|
Haloperidol |
Injection: 5mg/1mL ampoule; Tablet 5mg |
B |
|
Hydrocortisone |
Powder for injection (as sodium succinate) 100mg in vial |
A |
|
Hyoscine butyl bromide |
Tablet 10mg |
A |
|
Hyoscine butyl bromide |
Injection: 20mg/mL |
B |
|
Loperamide |
Tablet 2mg |
B |
|
Imipramine |
Tablet 25mg |
C |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
Bethametasone |
Injection: 4mg/mL |
D |
|
Cetirizine |
Oral solution 5mg/5mL; Tablet (hydrochloride) 10mg |
A |
|
Chlorpheniramine |
Injection (maleate 10mg/mL in 1mL ampoule); Elixir (maleate) 2mg/5mL; Tablet (maleate) 4mg |
A |
|
Desloratadine |
Tablet: 5 mg film-coated |
S |
|
Dexamethasone |
Injection: 4mg/mL in 1mL ampoule (as disodium phosphate salt); |
B |
|
Epinephrine (Adrenaline) |
Injection: 1mg (as hydrochloride or hydrogen tartrate) in 1mL ampoule |
A |
|
Loratadine |
Syrup 5mg/5mL; Tablet 10mg |
C |
|
Promethazine |
Injection (hydrochloride) 25mg/mL in 2mL; Syrup 5mg/5mL; Tablet (hydrochloride) 25mg |
A |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
4.1 Antidotes (Non-specific) |
||
|
Charcoal, activated |
Tablet or Powder, 50g |
A |
|
Magnesium sulfate |
Powder salt, 5g |
C |
|
4.2 Antidotes (Specific) |
||
|
Acetylcysteine |
Injection: 200mg/mL in 10mL ampoules |
C |
|
Atropine |
Injection 1mg (as sulfate in 1mL ampoule) |
A |
|
Calcium Gluconate |
Injection 100mg/mL in 10mL |
A |
|
Deferoxamine |
Injection 500mg (mesylate)in vial |
D |
|
D-penicillamine |
Tablet 250mg |
D |
|
Dimercaprol |
Injectable 50mg/mL in 2mL ampoule |
D |
|
Ethylenediaminetetra-acetic acid (EDTA) |
Injection 200mg/mL in 5mL |
D |
|
Flumazenil |
Injection:100mcg/mL in 5mL |
D |
|
Pralidoxime |
Injection 600mg |
S |
|
Sodium Bicarbonate 8.4% |
Injection 10mLs |
C |
|
Sugammadex |
Injection 100mg/mL |
S |
|
Succimer |
Capsule 100mg (2,3-Dimercaptosuccinic acid) |
D |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
Carbamazepine |
Syrup 100mg/5mL; Tablet 100mg; 200mg |
A |
|
Clonazepam |
Tablet 0.5mg, 2mg |
D |
|
Diazepam |
Tablet 5mg |
C |
|
Injection 5mg/mL in ampoule 2mL |
A |
|
|
Lamotrigine |
Tablet 100mg, 200mg |
S |
|
Levetiracetam |
Injection 5mg/mL, 10mg/mL, 15mg/mL, 100mg/mL, Tablet 250mg, 500mg, 750mg, 1000mg |
S |
|
Lorazepam |
Injection: 2mg/mL in ampoule; 4mg/mL in ampoule, Tablet 1mg/2mg |
C |
|
Magnesium sulfate |
Injection 50mg/mL in 10mL vial |
A |
|
Phenobarbital |
Injection (as sodium salt), 100mg in 2mL ampoule |
A |
|
Tablet (as sodium) 30mg, 100mg |
A |
|
|
Phenytoin |
Suspension (as sodium salt) 30mg/5mL; Tablet/Capsule (as sodium salt) 50mg, 100mg, Injection 100mg/2mL |
C |
|
Pregabalin |
Tablet/Capsule 75mg, 100mg; 150mg |
D |
|
Sodium Valproate |
Tablet 200mg, 500mg |
C |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
6.1 Anthelminthics |
||
|
6.1.1.Intestinal anthelminthics |
||
|
Albendazole |
Suspension 100mg/5mL in 30mL bottle; Tablet 200mg, 400mg, chewable |
A |
|
Mebendazole |
Suspension 100mg/5mL in 30mL bottle; Tablet 100mg, chewable |
A |
|
6.1.2 Antifilariasis |
||
|
Ivermectin |
Tablet 3mg, 6mg |
A |
|
6.1.3 Anti-schistosomiasis and Other Anti-trematode Medicines |
||
|
Praziquantel |
Tablet 600mg |
A |
|
Albendazole |
Tablet 200mg, 400mg |
A |
|
6.2 Antibacterial |
||
|
6.2.1 Access Group Antibiotics |
||
|
Ampicillin |
Powder for injection (as sodium salt) 250mg, 500mg in vial |
A |
|
Ampicilin + cloxacillin |
Capsule 250/250mg, injection |
B |
|
Amoxicillin |
Capsule (as trihydrate) 250mg; Dispersible tablet 250mg, 125mg |
A |
|
Amoxicillin + Clavulanic acid |
Powder for suspension (as trihydrate) 125mg+ 31.25mg (as potassium salt) in 5mL AND 250mg amoxicillin + 62.5mg clavulanic acid/5mL; Tablet (as trihydrate) 500mg + 125mg clavulanic acid (as potassium salt) |
B |
|
Amoxicillin + Clavulanic acid |
Powder for injection 500mg (as sodium), + 100mg (as potassium salt) in vial |
C |
|
Benzathine benzyl penicillin |
Powder for injection 1.44g (2,400,000 IU) in vial |
A |
|
Benzyl Penicillin |
Powder for injection (as sodium or potassium salt) 3g (5,000,000 IU) in vial |
A |
|
Cephalexin |
Capsule 250mg (as monohydrate); Powder for reconstitution 125/5mi; 250mg/mL |
B |
|
Cloxacillin |
Powder for injection (as sodium salt) 250mg, 500mg in vial |
B |
|
Doxycycline |
Capsule (as hydrochloride), 100mg |
A |
|
Erythromycin |
Powder for suspension (as ethylsuccinate), 125mg/5mL in 100mL bottle; Tablet (as stearate or ethyl succinate), 250mg, film coated |
A |
|
Flucloxacillin + Amoxicillin |
Tablet 500mg (as combination) ; |
C |
|
Flucloxacillin |
Injection (sodium) 250mg; 125mg/5mL Oral solution |
C |
|
Metronidazole |
Suspension as (benzoate) 200mg/5mL in 100mL; Tablet 200mg |
A |
|
Injection (IV) 5mg/mL in 100mL bottle |
B |
|
|
Nitrofurantoin |
Tablet 100mg |
A |
|
Phenoxymethylpenicillin |
Powder for suspension 125mg/5mL; (as potassium salt), Tablet 250mg |
A |
|
Tetracycline |
Capsule 250mg |
S |
|
Oxytetracycline |
Eye ointment 1% (hydrochloride) |
A |
|
6.2.2 Watch Group Antibiotics |
||
|
Ampicillin + Sulbactum |
Powder for injection (ampicillin 1g/sulbactam 0.5g), (ampicillin 2g/sulbactam 1g), (ampicillin 10g/sulbactam 5g) |
C |
|
Azithromycin |
Capsule/Tablet (as dihydrate) 250mg, 500mg; Oral liquid 200mg/5mL |
B ( level A for STI only) |
|
Clarithromycin |
Tablet 250mg, 500mg |
C |
|
Chloramphenicol |
Oily injection 0.5g (as sodium succinate)/mL in 2mL ampoule; Powder for injection (as sodium succinate) 1g, 125mg/5mL injection (as Phosphate), 150mg/mL in 2mL ampule |
B (Reserved for meningitis) |
|
Ceftriaxone |
Injection 250mg, 500mg, 1g in vial |
B ( level A for STI only) |
|
Ceftriaxone+sulbactam |
Injection 1.5g vial |
D |
|
Ciprofloxacin |
Tablet (as hydrochloride) 250mg, 500mg |
A |
|
Ciprofloxacin |
Solution for IV infusion 2mg/mL in 100mL |
C |
|
Gentamicin |
Injection (as sulfate) 40mg/mL in 2mL ampoule, 20mg/mL in 2 mL ampoule |
A |
|
Piperacillin + tazobactam |
Powder for injection 2g (as sodium salt) + 250mg (as sodium salt); 4g (as sodium salt) + 500mg (as sodium salt) in vial |
S |
|
Sulfamethoxazole + triemethoprim |
Suspension (Sulphamethoxazole 200 mg/5mL + trimethoprim 40mg/5mL in 100mL bottle; Tablet 480mg; Sulphamethoxazole 400mg/trimethoprim 80mg |
A |
|
Ceftazidime |
Powder for injection (as pentahydrate) 250mg in vial |
D |
|
Cefixime |
Capsule 200mg/ 400mg |
S (A for STI and Typhoid) |
|
Cefuroxime |
Powder for Injection 250mg, 750mg, 1.5g (as sodium salt) in vial |
D |
|
Oral suspension 125mg/5mL, 250mg/5mL; Tablet 250mg, 500mg; injection |
D |
|
|
6.2.3 Reserve Group Antibiotics |
||
|
Amikacin |
Injection 250mg/mL (as sulfate) |
S |
|
Cefepime |
Injection 1000mg |
S |
|
Clindamycin |
Capsule 150mg (as hydrochloride) |
S |
|
Injection (as phosphate) 150mg/mL in 2mL ampule |
S |
|
|
Colistin |
Powder for Injection 1MIU per vial |
S |
|
Dapsone |
Tablet 100mg |
S |
|
Meropenem |
Injection 500mg, 1000mg |
S |
|
Vancomycin |
Capsule: 125mg; 250mg (as hydrochloride) |
S |
|
Powder for injection 250mg (as hydrochloride) in vial |
S |
|
|
6.2.3 Antileprosy Medicines |
||
|
Clofazimine |
Capsule: 50mg; 100mg |
A |
|
Dapsone |
Dapsone Tablet 50mg, 100mg |
A |
|
Rifampicin |
Tablet 25mg; 50mg; 100mg |
A |
|
6.2.4 Antituberculosis Medicines |
||
|
Ethambutol |
Tablet (as hydrochloride) 400mg |
A |
|
Ethambutol+Isoniazide |
Tablet 400mg + 100mg |
A |
|
Ethionamide |
Tablet 125mg, 250mg |
S |
|
Isoniazid |
Tablet 100mg |
A |
|
Pyrazinamide |
Tablet 500mg |
A |
|
Rifampicin+Isoniazid |
Capsule/Tablet,150mg+75mg, 50mg+150mg |
A |
|
Rifampicin+Isoniazid+Pyrazinamid e+Ethambutol |
Tablet 150mg + 75mg + 400mg + 275mg |
A |
|
6.2.5 Reserved Second-line for Treatment of Multidrug Resistance Tuberculosis (MDR-TB) |
||
|
Cycloserine |
Tablet 250mg |
S |
|
Bedaquiline |
Tablet 100mg |
S |
|
Capromycine |
Powder for injection 1g (as sulfate) in a vial |
S |
|
Delamanide |
Tablet 50mg |
S |
|
Kanamycin |
Powder for injection: 1g (as sulfate) in vial |
S |
|
Levofloxacin |
Tablet 250mg |
S |
|
Linezolid |
Injection for intravenous administration: 2mg/mL in 300mL bag; Tablet 400mg; 600mg |
S |
|
Moxifloxacin |
Tablet 400mg |
S |
|
p-Amino salicylic acid (PAS) |
Granules 4g in a sachet; Tablet 500mg |
S |
|
6.3 Antifungal Medicines |
||
|
Amphotericin B |
Amphotericin B Powder for injection 50mg in vial |
S |
|
Clotrimazole |
Clotrimazole Vaginal cream (nitrate) 1%, 10%; Clotrimazole Pessaries 100mg; 500mg ; Topical cream/Ointment |
A |
|
Fluconazole |
IV infusion 2mg/mL in vial |
C |
|
Tablet/Capsule 150mg, 200mg |
A |
|
|
Flucytosine |
Isotonic infusion solution containing flucytosine (1%)and 0.805% sodium chloride |
S |
|
Isotonic infusion solution containing flucytosine (1%)and 0.805% sodium chloride |
S |
|
|
Griseofulvin |
Tablet 500mg |
A |
|
Itraconazole |
Capsule 100mg |
D |
|
Miconazole |
Miconazole Oral gel 2%; Vaginal Pessaries, Topical cream/ointment |
C |
|
Nystatin |
Suspension oral 100,000 IU/mL |
A |
|
Terbinafine |
Tablet 250mg ; Topical cream |
C |
|
6.4 Antiviral Medicines |
||
|
6.4.1 Antiherpes Medicines |
||
|
Acyclovir |
Cream 5%; Tablet 200mg, 400mg, |
B |
|
Injection 500mg/Vial |
D |
|
|
Valganciclovir |
Tablet 450mg |
S |
|
6.4.2 Antiretrovirals (ARVs) |
||
|
6.4.2.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors |
||
|
Abacavir (ABC) |
Tablet: 300mg (as sulfate) |
A |
|
Lamivudine (3TC) |
Oral Liquid 50mg/mL; Tablet: 150mg |
A |
|
Tenofovir disoproxil fumarate (TDF) |
Tablet: 300mg |
A |
|
Zidovuine (AZT) |
Capsule 250mg; Oral liquid 50mg/5mL |
A |
|
6.4.2.2 Non-nucleoside Transcriptase Inhibitors |
||
|
Efavirenz (EFV) |
Tablet: 200mg; 600mg |
A |
|
Nevirapine (NVP) |
Oral liquid: 50mg/5mL; Tablet 50mg (dispersible); 200mg |
A |
|
6.4.2.3 Protease Inhibitors |
||
|
Atazanavir |
Tablet 100mg; 300mg (as sulfate) |
C |
|
Atazanavir + Ritonavir |
Tablet: 300mg (as sulfate) + 100mg |
C |
|
Lopinavir + Ritonavir (LPV/r) |
Capsule 40mg + 10mg; Oral liquid 400mg + 100mg/5mL; Tablet 100mg + 25mg; 200mg + 50mg |
C |
|
Ritonavir |
Oral liquid 400mg/5mL; Tablet 25mg; 100mg |
C |
|
Darunavir |
Tablet 75mg, 400mg, 600mg, 800mg |
S |
|
6.4.2.4 Integrase Inhibitors |
||
|
Raltegravir |
Tablet 25mg, 100mg, 400mg |
S |
|
6.4.2.5 Fixed Dose Combinations |
||
|
Abacavir/Lamivudine |
Dispersible Tablet 60/30mg; Dispersible tablet; 120/60mg; Tablet 600/300mg Scored |
A |
|
Tenofovir /Emtricitabine |
Tablet 300/200mg |
A |
|
Tenofovir/Emtricitabine/Efavirenz |
Tablet 300/200/600mg |
A |
|
Tenofovir/Lamivudine/Efavirenz |
Tablet 300/300/600mg |
A |
|
Tenofovir/Lamivudine/Dolutegravir |
Dispersible tablet 60/30mg; Tablet 300/300/50mg |
A |
|
Zidovudine/Lamivudine |
Tablet 300/150mg |
A |
|
Zidovudine/Lamivudine/Nevirapine |
Tablet 300/150/200mg |
A |
|
6.4.2.6 Medicines for Prevention of Opportunistic Infections |
||
|
Isoniazide |
Tablet 300mg |
A |
|
Pyridoxine |
Tablet 25mg |
B |
|
Sulphamethoxazole + trimetoprim |
Tablet 400mg + 80mg |
A |
|
6.4.3 Antihepatitis Medicines |
||
|
6.4.3.1 Medicines for Hepatitis-B |
||
|
Entecavir |
Tablet 0.5mg |
S |
|
Tenofovir disoproxil fumarate (TDF) |
Tablet: 300mg |
A |
|
6.4.3.2 Medicines for Hepatitis-C |
||
|
Ledipasvir |
Tablet 90mg |
S |
|
Ribavirin |
Tablet 600mg |
S |
|
Sofosbuvir |
Tablet 400mg |
S |
|
6.5 Antiprotozoal Medicines |
||
|
6.5.1 Antiamoebic and Antigiardiasis Medicines |
||
|
Metronidazole |
Suspension 200mg/5mL; Tablet 200mg |
A |
|
Tinidazole |
Tablet 500mg |
B |
|
6.5.2 Anti-malarial Medicines |
||
|
Artemether/Lumefantrine (ALU) |
Tablet 20mg/120mg |
A |
|
Artemether |
Injection 80mg/mL ampoules |
B |
|
Artesunate |
Injection: ampoule, containing 60mg anhydrous artesunic acid with separate ampoule of 5% sodium bicarbonate solution |
A |
|
Dihydroartemisinin+Piperaquine (DPQ) |
Tablet 40mg+320mg, 20mg+160mg |
C |
|
Primaquine |
Tablet (as phosphates) 2.5mg, 7.5mg, 15mg |
A (restricted to few HFs under the project) |
|
Sulfadiazine |
500mg tablet |
D |
|
Pyrimethamine |
25mg tablet |
D |
|
6.5.3 Malaria Prophylaxis |
||
|
Sulfadoxine + Pyrimethamine |
Tablet 500mg + 25mg |
A |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
7.1 Medicines for Treatment of Acute Attack |
||
|
Acetylsalicylic acid |
Tablet 300mg |
A |
|
Ibuprofen |
Tablet 200mg, 400mg |
A |
|
Ergotamine tartarate |
Tablet 1mg, 2mg |
C |
|
7.2 Medicines for Prophylaxis |
||
|
Propranolol |
Tablet 40mg as hydrochloride |
A |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
5-fluorouracil |
Injection: 250mg; 500mg; 000mg; |
S |
|
Abiraterone acetate |
Tablet 250mg |
S |
|
Actinomycin D |
Powder for injection: 500 micrograms in vial |
S |
|
Alfuzocin |
Tablet 10mg |
D |
|
Allopurinol |
Tablet 100mg; 300mg |
B |
|
Anastrazole |
Tablet 1mg |
S |
|
Antithymocite globulin (ATG) (rabbit/horse) |
Injection 25mg/mL in 5mL | S |
|
Azacitadine |
Injection 25mg/mL |
S (with control) |
|
Azathioprine |
Tablet 50mg, 75mg, 100mg |
S |
|
basiliximab |
Injection 20mg |
S |
|
Bicalutamide |
Tablet 150mg, 50mg |
S |
|
Bleomycin |
Powder for injection: 15 IU (as sulfate) in vial |
S |
|
Bortezomib |
Injection 3.5mg/vial |
S |
|
Capecitabine |
Tablet 500mg |
S |
|
Carboplatin |
Injection 10mg/mL |
S |
|
Chlorambucil |
Tablet 2mg |
S |
|
Cisplatin |
Powder for injection 50 mg; 10mg in vial. |
S |
|
Cyclophosphamide |
Injection |
S |
|
Cyclosporine |
Injection: 50 mg/mL in 1-mL ampoule; Capsule: 25 mg; 50mg; 100mg |
S |
|
Dacarbazine |
Powder for injection: 100 mg in vial; 200mg/; 500mg |
S |
|
Danazol |
Capsule 100mg |
S (hematology special) |
|
Docetaxel |
Concentrate for infusion 120mg; 80mg |
S |
|
Doxorubicin |
Injection 10mg; 20mg, 50mg |
S |
|
Dutasteride |
Tablet 0.5mg |
S |
|
Etoposide |
Capsule: 100 mg; Injection 100 mg/mL; Injection 50mg/5mL |
S |
|
Everolimus |
Tablet 0.25, 0.5mg |
S |
|
Febuxostat |
Tablet 40mg; 80mg |
S |
|
Filgrastim |
Injection 5mcg |
S |
|
Finasteride |
Tablet 5mg |
D |
|
Folinic acid |
Tablet 15mg, injection 6mg |
S |
|
Gemcitabine |
Injection 200mg; 500mg; 1000mg |
S |
|
Goserelin |
Injection 3.6mg, 10.8mg |
S |
|
Hydroxychloroquine |
Tablet 200mg |
S |
|
Hydroxyurea |
Capsule 500mg |
S |
|
Ifosfamide |
Injection 1g/20mL |
S |
|
Imatinib |
Tablet 400mg |
S |
|
Irinotecan |
Injection 180mg/mL |
S |
|
Lenalidomide |
Tablet 25mg |
S |
|
Leucovorin |
Injection 200 mg/mL |
S |
|
Mesna |
Injection, 100mg/mL; Tablet 400mg |
S |
|
Methotrexate |
Tablet 2.5mg; Injection 50 mg/5mL |
S |
|
Mycophenolate Sodium |
Tablet 360mg |
S |
|
Mycophenolate Mofetil |
Tablet 500mg |
S |
|
Oxaliplatin |
Powder for injection 50mg; 100mg in vial; |
S |
|
Paclitaxel |
Injection 260mg vial |
S |
|
Rituximab |
Injection 375 mg |
S |
|
Sirolimus |
Tablet 1mg, 2mg |
S |
|
Tacrolimus |
Tablet 0.5mg; 1mg; 2mg Ointment 0.1% |
S |
|
Tamsulosin |
Tablet 0.4mg |
D |
|
Tamoxifen |
Tablet 20mg |
D |
|
Temozolomide |
Tablet 200mg |
S |
|
Thalidomide |
Tablet 200mg |
S |
|
Trastuzumab |
Injection 440mg; 150mg; 600mg; 500mg |
S |
|
Vinblastine |
Injection 10mg |
S |
|
Vincristine |
Powder for injection: 2 mg; 5 mg (sulfate) in vial. |
S |
|
Zolendronic acid |
Injection 4mg; 5mg |
S |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
9.1 Adrenal Hormones and Synthetic Substitutes |
||
|
Betamethasone |
Injection 4mg/mL |
D |
|
Dexamethasone |
Tablet 0.5mg; 4mg |
D |
|
Injection (as sodium phosphate) 10mg/mL Implant 75mg |
B |
|
|
Hydrocortisone |
Powder for Solution for Injection/Infusion 100 mg (as sodium succinate) |
A |
|
Methylprednisolone |
1000 mg powder and solvent for solution for injection/infusion; Tablet 4mg; 8mg; |
D |
|
Metyrapone |
Tablet 250mg |
S |
|
Prednisolone |
Tablet 5mg |
A |
|
Triamcinolone |
Injection 40mg/mL; Cream 0.1% |
S |
|
9.2 Oestrogens |
||
|
Ethinyloestradiol |
Tablet 50mcg |
A |
|
9.3 Ovulation Inducers |
||
|
Clomiphene |
Tablet 50mg |
C |
|
9.4 Progesterone |
||
|
Dydrogestrone |
10mg tablet |
S |
|
Etonorgestrel |
Implant 68mg |
A |
|
Levonorgestrel |
Tablet 0.03mg, 0.07mg, 0.75mg |
A |
|
Implant 75mg |
A |
|
|
Medroxyprogesterone |
Injection acetate (depot) 150mg |
A |
|
Norethisterone |
Tablet 5mg |
C |
|
9.5 Androgens |
||
|
Testosterone |
Injection, 30 mg/1.5mL;100mg/mL; 200mg/mL; Cream |
S |
|
9.6 Contraceptives |
||
|
Ethinyloestradiol + Norgestrel |
Tablet 0.03mg + 0.3mg |
A |
|
Ethinylestradiol Levonorgestrel |
Tablet 0.03mg + 0.15mg |
A |
|
Ethinylestradiol Desogestrel |
Tablet 0.03mg + 0.15mg |
A |
|
9.7 Thyroid, Parathyroid Hormones and Antagonists |
||
|
Carbimazole |
Tablet 5mg |
C |
|
Potassium Iodide Solution |
Iodine 2mg + Potassium Iodide 4mg/g in water (prepare from raw material) |
B |
|
Levothyroxine |
Tablet (sodium salt) 0.05g |
D |
|
Iodized oil Capsule |
Iodized oil Capsule with nipple 240mg/0.5mL and 480mg iodine/mL |
A |
|
Iodized oil |
Injection |
C |
|
Propylthiouracil |
Tablet 50mg |
D |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
Benzhexol |
Tablet (hydrochloride) 5mg |
B |
|
Bromocriptine |
Tablet 2.5mg |
C |
|
Cabergoline |
Tablet 0.5mg |
S |
|
Levodopa/Carbidopa |
Tablet 100mg + 25mg |
D |
|
Selegiline |
Tablet 5mg |
S |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
11.1 Antianaemia Medicines |
||
|
Erythropoietin |
2000 unit/Ml; 4000 units/mL |
S |
|
Ferrous |
200mg ( sulfate or as fumarate) |
A |
|
Ferrous salts |
Oral liquid: Equivalent to 25mg iron (as sulfate)/mL; Tablet: Equivalent to 60mg iron |
A |
|
Folic acid |
Folic acid Tablet 5mg |
A |
|
Hydroxocobalamin (Vitamin B12) |
Injection 1mg/mL |
C |
|
11.2 Medicines Affecting Coagulation |
||
|
Desmopressin (Move to anti-diuretics) |
Injection 4mcg/mL, Tablet 0.2mg | S |
|
Etamsylate |
Tablet 500mg |
C |
|
Low molecular Weight heparin |
Injection 100mg/mL |
S |
|
Phytomenadione (Vit K1) |
Injection 0.5 mg/mL, 2mg/mL in 2mL ampoule; |
B |
|
Protamine sulfate |
Injection 10mg/mL in 5mL ampoule |
B |
|
Rivaroxaban |
Tablet 15mg, 20mg |
S |
|
Unfractionated Heparin Sodium |
Injection (sodium salt) 1,000 IU/mL in 5mL ampoule |
B (Under specialist supervision) |
|
Tranexamic acid |
Injection 100mg/mL in 5mL ampoule; Syrup 500mg/5mL in 300mL bottle; Tablet 500mg |
C |
|
Warfarin |
Tablet: 1mg; 2mg; 5mg (sodium salt) |
C |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
12.1 Blood and Blood Components |
||
|
Fresh frozen plasma (FFP) |
Fresh frozen plasma (FFP) Bags |
D |
|
Platelets |
Platelets |
D |
|
Red blood cells. |
Packed red blood cells. |
D |
|
Whole blood |
Whole blood |
B |
|
12.2 Plasma-Derived Medicines |
||
|
12.2.1 Human Immunoglobulins |
||
|
Anti-rabies immunoglobulin |
|
A |
|
Anti-tetanus immunoglobulin |
|
A |
|
Human Immunoglobulin G |
|
S |
|
12.2.2 Blood Coagulation Factors |
||
|
Eltrombopag |
Tablet 25mg |
S |
|
Factor VIII concentrate |
Factor VIII concentrate 500IU |
S |
|
Factor IX concentrate |
Factor IX concentrate500 IU |
S |
|
12.3 Plasma Substitutes |
||
|
Albumin |
Infusion 5%; 25% |
S |
|
Polygeline |
Polygeline IV solution 3.5%, 500mL bottles |
S |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
13.1 Antianginal Medicines |
||
|
Bisoprolol |
Tablet 5mg; 10mg |
S |
|
Glyceryl trinitrate |
Spray 400 micrograms/metered dose, sublingual spray |
C |
|
Isosorbide Dinitrate |
Tablet 10mg, 20mg |
C |
|
Labetalol |
Tablet 100mg, 200mg ; Injection 5mg/mL |
C |
|
Nifedipine |
Slow-release Capsule/Tablet 10mg; 20mg |
B |
|
Nitroglycerin |
Injection/Infusion 25mg/250mL; 50mg/250mL; 100mg/250mL |
S |
|
Propranolol |
Tablet 40mg |
A |
|
13.2 Antiarrhythmic Medicines |
||
|
Adenosine |
Injection 3mg/mL in Saline |
S |
|
Amiodarone |
Injection 30mg/mL in 10mL ampoule; Tablet 100mg |
S |
|
Sotalol |
Tablet 80 mg, 120 mg, 160 mg, 240 mg; Oral solution 5mg/Ml; Injection 15mg/mL |
S with control |
|
Verapamil |
Injection 2.5mg/mL, 2mL ampoule; Tablet 40mg 80mg |
S |
|
13.3 Antihypertensive Medicines |
||
|
Amlodipine |
Tablet 5mg, 10mg |
C |
|
Atenolol |
Tablet 50mg |
B |
|
Candesartan |
Tablet 16mg; Tablet in fixed combination |
S |
|
Captopril |
Tablet 12.5mg, 25mg |
B |
|
Carvedilol |
Tablet 6.25, 12.5mg |
C |
|
Clonidine |
Injection 500mcg/mL; Tablet 0.1 mg, 0.2 mg and 0.3 mg |
S |
|
Diltiazem |
Tablet 60mg |
D |
|
Doxazosin |
Tablet 2mg, 4mg |
S |
|
Enalapril |
Tablet 2.5mg, 5mg (as hydrogen maleate) |
C |
|
Esmolol |
Injection 10g/mL |
S |
|
Hydralazine |
Tablet 25mg |
B |
|
20mg Powder for Injection/Infusion |
C |
|
|
Irbesartan |
Tablet 150mg, 300mg; Tablet in fixed combination |
S |
|
Lisinopril |
Tablet 5mg, 10mg |
C |
|
Losartan |
Tablet 50mg; Tablet in fixed combination |
C |
|
Nimodipine |
Capsule 30mg |
S |
|
Methyldopa |
Tablet 250mg |
A |
|
Metolazone |
Tablet 5mg |
S |
|
Metoprolol |
Tablet 50mg |
C |
|
Injection 1mg/mL |
S |
|
|
Telmisartan |
Tablet 40mg, 80mg; Tablet in fixed combination |
|
|
13.4 Medicines Used in Heart Failure |
||
|
Candesartan |
Tablet 8mg |
C |
|
Dobutamine |
Injection 250mg/5mL |
S |
|
Dopamine |
Injection 250mg |
S |
|
Digoxin |
Injection 250mg/mL |
D |
|
Tablet 0.25mg |
D |
|
|
Ivabradine |
Tablet 5mg |
S |
|
13.5 Diuretics |
||
|
Furosemide |
Injection 10mg/mL; Tablet 40mg |
B |
|
Eplerenone |
Tablet 25mg, 50mg |
S |
|
Bendrofluazide |
Tablet 5mg |
A |
|
Hydrochlorothiazide |
Tablet 25mg; 12.5mg |
D |
|
Mannitol |
Injectable solution: 10%; 20% |
C |
|
Spironolactone |
Tablet 12.5mg, 25mg |
C |
|
Torsemide |
Tablet 2.5mg, 5mg; 10mg |
S |
|
13.6 Antithrombotic Medicines |
||
|
13.6.1 Anti- Platelet Medicines |
||
|
Acetylsalicylic acid |
Tablet: 75mg, 100mg |
A |
|
Clopidogrel |
Tablet: 75mg; 300mg |
D |
|
Prasugrel |
Tablet 10mg |
S (with special permission) |
|
Ticagrelor |
Tablet 60mg, 90mg |
S (with special permission) |
|
13.6.2 Thrombolytics |
||
|
Alteplase |
Powder for injection: 50mg vial |
S |
|
Streptokinase |
Powder for injection: 1.5 million IU in vial. |
S |
|
13.7 Lipid Lowering Medicines |
||
|
Atorvastatin |
Tablet 10mg; 20mg; 40mg |
B |
|
Fenofibrate |
Capsule 200mg |
D |
|
Rosuvastatin |
Tablet: 10mg ; 20mg |
S |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
14.1 Antifungal Medicines |
||
|
Benzoic acid Compound (whitfied's) |
3% salicylic acid and 6% benzoic acid ointment |
A |
|
Clotrimazole |
Cream 1% |
A |
|
Miconazole |
Cream (nitrate) 2% |
C |
|
Terbinafine |
Cream 1%, |
C |
|
14.2 Anti-infective Medicines |
||
|
Fusidic acid |
Cream 2% |
C |
|
Gentian Violet |
1%, aqueous solution |
A |
|
Mupirocin |
Ointment 2% |
C |
|
Potassium permanganate |
Potassium permanganate Solution 1:4000 |
A |
|
Povidone iodine |
Solution 10% |
A |
|
Silver Sulfadiazine |
1% Cream |
A |
|
14.3 Anti-nflammatory and Anti-pruritic Medicines |
||
|
Betamethasone |
cream or ointment 0.1% ( as valerate) |
C |
|
Calamine |
Lotion 15.0% w/v |
A |
|
Clobetasol propionate |
Cream 0.05%; 0.1% |
D |
|
Fludrocortisone |
Tablets 0.1 mg (as acetate) |
S |
|
Hydrocortisone |
Hydrocortisone Cream 0.5% |
A |
|
Mometasone furoate |
Ointment/Cream containing 0.1% contains mometasone furoate, |
S |
|
Triamcinolone |
Injection 40mg/mL as Acetonide |
S |
|
14.4 Medicines Affecting Skin differentiation and Proliferation |
||
|
All-trans-retinoic acid (ATRA) |
Tablet 10mg, 20mg, injection |
S |
|
Benzoyl peroxide |
Gel 2.5%, 5% and 10% |
A |
|
Coal tar |
Solution 5% (prepare from raw materials) |
C |
|
Isotretinoin |
0.05% cream, Capsule 10mg, 20mg |
S |
|
Podophyllin Solution |
Solution 10-25% (prepare from raw materials) |
D |
|
Salicylic acid |
Topical solution 5% (prepare from raw materials) |
C |
|
Silver nitrate pencil |
Silver nitrate pencil |
C |
|
Tretinoin cream |
2.5% cream |
S |
|
14.5 Scabicides and Pediculicides |
||
|
Benzyl benzoate Emulsion |
Emulsion: 25% |
A |
|
Lindane |
Lotion 1% |
C |
|
14.6 Sunscreen Protector |
||
|
Sunscreen protecting factor (SPF 30+) |
Sun screen cream 30+ | C |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
15.1 Antiulcer Medicines |
||
|
Antiacid Mixture |
Antiacid Mixture containing magnesium trisilicate + aluminium hydroxide and Simethicone |
B |
|
Bismuth Subgallate |
Tablet 200mg |
D |
|
Esomeprazole |
Tablet 20mg; 40mg |
S |
|
Lansoprazole |
Tablet 30mg |
C |
|
Magnesium trisilicate Tablet |
Tablet (250mg magnesium trisilicate + 120mg dried aluminium hydroxide) |
A |
|
Mesalazine |
Tablet 400mg, 500mg, 800mg |
S |
|
Octreotide |
Injection 50mcg; 100mcg |
S (Special permission) |
|
Omeprazole |
Tablet 20mg |
A |
|
Pantoprazole |
Tablet 40mg; Powder for injection 40mg |
C |
|
Terlipressin |
0.12mg/mL solution for injection (acetate) |
S |
|
15.2 Drugs affecting Intestinal Secretion and Antispasmodics |
||
|
Cholestyramine |
Cholestyramine Powder 4g per Sachet |
S |
|
Hyoscine butylbromide Tablet |
Hyoscine butylbromide Tablet 10mg |
A |
|
Hyoscine butylbromide Injection |
Hyoscine butylbromide Injection 20mg/mL; 1mL ampoule |
C |
|
Inflixmab |
Injection 100mg |
S (Special permit) |
|
Mebeverine |
Tablet 135mg |
D |
|
Pancreatic |
Supplement Enzyme |
S |
|
Ursodeoxycholic acid |
Tablet/capsule 300mg |
S |
|
15.3 Anti-emetics |
||
|
Domperidone |
Tablet 10mg |
D |
|
Doxylamine |
Tablet 25mg |
C |
|
Metoclopramide |
Tablet 10mg; Injection 5mg/mL; Suspension 5mg/5mL |
C |
|
Promethazine |
Tablet (hydrochloride/theoclate) 25mg; Injection (as hydrochloride) 25mg/mL; Elixir 5mg/5mL (as chloral hydrate) |
A |
|
Ondansetron |
Tablet 8mg, Injection 2mg/mL |
S |
|
15.4 Cathartics |
||
|
Bisacodyl |
Tablet 5mg |
A |
|
Lactulose |
Solution 3.1 - 3.7g/5mL, 200mL bottle |
C |
|
L-Ornithine L-Aspartate |
Granules; Injection |
S |
|
15.5 Anti-Haemorrhoids |
||
|
Local anaesthetic + astringent and anti-inflammatory |
Suppositories/ointment (zinc oxide 25mg |
B |
|
15.6 Medicines Used in Diarrhoea |
||
|
Loperamide |
Tablet/Capsule (hydrochloride) 2mg |
B |
|
Oral Rehydration Salts (ORS) |
Low osmolality sachet to make 1 litre of solution containing Sodium chloride 2.6g, Sodium citrate 2.9g, Potassium chloride 1.5g and Glucose 20.5g) |
A |
|
Zinc |
Tablet dispersible (equivalent to 20mg elemental zinc) |
A |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
Empagliflozin |
Tablet 10mg |
S (with special permit) |
|
Glibenclamide |
Tablet 5mg |
A |
|
Gliclazide |
Tablet 40mg; 80mg; 30mg; 60mg |
A |
|
Glimepiride |
Tablet 1mg; 2mg |
C |
|
Glucagon |
Powder for reconstitution 10mg/vial |
S |
|
Insulin |
Rapid acting; Injection: 40 IU/mL; 100 IU/Ml |
|
|
Rapid acting; Injection: 40 IU/mL; 100 IU/Ml |
A |
|
|
Rapid acting; Injection: 40 IU/mL; 100 IU/Ml |
A |
|
|
Rapid acting; Injection: 40 IU/mL; 100 IU/Ml |
A |
|
|
Rapid acting; Injection: 40 IU/mL; 100 IU/Ml |
S |
|
|
Metformin |
Tablet 500mg; 750; 850MG; 1000MG; SR |
A |
|
Pioglitazone |
15mg |
D |
|
Phenoxybenzamine |
Tablet 10 mg |
S |
|
Sitagliptin |
Tablet 50mg; 100mg |
S |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
17.1 Sera and Immunoglobulins |
||
|
Anti D immunoglobulin |
Injection 150mg; 300mg |
C |
|
Antirabies immune globulin |
Injection 400IU/mL; 10,000IU/5mL |
A |
|
Anti-venom immunoglobulin |
Snake venom polyvalent Antiserum injection (|Central African type) |
A |
|
Diphtheria antitoxin |
Injection: 10,000 IU; 20,000 IU vial |
A |
|
Tetanus Immunoglobulin |
Tetanus Immunoglobulin (human) – 250 IU/mL,250 IU/2.5mL |
A |
|
17.2 Vaccines |
||
|
17.2.1 For Immunization |
||
|
BCG Vaccine |
Injection 20 doses vial (Bacillus Calmette Guerin) |
A |
|
DPT-HepB-Hib Vaccine |
Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus Influenza vaccine in vials of 10 doses |
A |
|
Hepatitis B |
Injection 10mcg/mL, 20mcg/mL, 40mcg/Ml |
B |
|
Human Papilloma Vaccine (HPV) |
Human Papilloma Vaccine (HPV) – 0.5mL per dose |
A |
|
Inactivated Polio Vaccine (IPV) |
Inactivated Polio Vaccine (IPV) |
A |
|
Measles-Rubella Vaccine |
Measles-Rubella Vaccine Injection 10 doses in vial |
A |
|
Oral Poliomyelitis Vaccine (OPV) |
Oral Poliomyelitis Vaccine (Live attenuated) Oral solution 20 doses in vial |
A |
|
Pneumococcal Conjugate Vaccine (PCV13) |
Pneumococcal Conjugate Vaccine (PCV13) -4 doses vial |
A |
|
Pneumococcal polysaccharide vaccine (PPSV-23) |
Vial |
S |
|
Rota Vaccine |
Rota Vaccine Oral solution |
A |
|
Tetanus (toxoid) Vaccine |
Tetanus (toxoid) Vaccine Injection 20 doses in 10mL vial |
A |
|
17.2.2 For Specific Groups for Individuals |
||
|
Human Diploid Cell Rabies Freeze dried rabies vaccine |
Human Diploid Cell Rabies Freeze dried rabies vaccine |
A |
|
Meningitis vaccine |
Injection |
C |
|
Yellow Fever Vaccine |
0.5mL dose |
C |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
Neostigmine |
Injection: 500microgram in 1mL ampoule; 2.5 (metilsulfate) in 1mL ampoule |
C |
|
Suxamethonium |
Injection: 50mg (chloride/mL in 2mL ampoule |
C |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
19.1 Anti-infective Agents |
||
|
Acyclovir ointment |
Acyclovir Eye ointment 3% |
C |
|
Ciprofloxacin |
Drops 0.3% |
C |
|
Chloramphenicol |
Drops 0.5%, 1%; Eye ointment 1% |
A |
|
Chlorhexidine |
Drops 0.2% |
S |
|
Dexamethasone+Chloramphenicol |
Drops 0.1%, 0.5% |
C |
|
Dexamethasone +Gentamicin |
Drops 0.1, 0.3% |
C |
|
Econazole |
Drops 5% |
S |
|
Natamycin |
Drops 5% |
S |
|
Ofloxacin |
Drops 0.3% |
D |
|
Oxytetracycline t |
Eye ointment 3% |
A |
|
Iodine |
Eye drops, 2.5-5% |
A |
|
19.2 Anti-allergy, Artificial Tears and Anti-inflammatory Agents |
||
|
Dexamethasone eye drops |
Drops 0.1% |
D |
|
Hydroxypropylmethylcellulose |
Drops 0.70% |
C |
|
Methylprednisolone acetate |
Injection 40mg/mL |
D |
|
Prednisolone eye drops |
Drops 0.5%, 1% |
D |
|
Oxymetazoline |
Drops 0.025% |
C |
|
Sodium cromoglycate drops |
Sodium cromoglycate 2%, 4% eye drops |
C |
|
Triamcinolone Acetatonide |
Injection 40mg/mL |
S |
|
19.3 Local and Topical Ocular Anaesthetic Agents |
||
|
Amethocaine eye drops |
Drops 0.5%w/v or 1.0%w/v |
A |
|
Tetracaine eye drops |
Drops .5%w/v |
C |
|
19.4 Miotics and Antiglaucoma |
||
|
Acetazolamide |
Tablet 250mg |
C |
|
Acetylcholine |
Injection; vial contains 20 mg acetylcholine chloride and 56 mg mannitol |
S |
|
Betaxolol |
Drops 0.25% -0.5% w/v |
D |
|
Brimonidine |
Drops 0.15 – 0.2% w/v |
D |
|
Dorzolamide |
Drops 20 mg/ml |
S |
|
Latanoprost |
Drops 0.005% w/v |
D |
|
Pilocarpine hydrochloride |
Drops 2 or 4% w/v |
C |
|
Prostamide bimatroprost |
Drops 0.03% w/v |
D |
|
Timolol |
Drops 0.25%, 0.5% w/v |
C |
|
19.5 Mydriatics and Anti-vascular Endothelial |
||
|
Atropine |
Drops 0.5%, 1% w/v; Ointment 1% |
B |
|
Cyclopentolate |
Drops 0.5%, 1% w/v |
C |
|
Tropicamide |
Drops 1% w/v |
S |
|
Tropicamide with Cyclopentolate |
Drops 0.5%, 1% w/v |
C |
|
Tropicamide with Phenylephrine |
Drops 0.8% / 5% w/v |
C |
|
19.6 Other Ocular Preparations |
||
|
5 –Fluoro Uracil |
1% eye drops |
D |
|
Ganciclovir |
Injection 2mg; ophthalmic gel, 0.15% |
S |
|
Mitomycin C |
5mg/vial, 10 mg/vial |
D |
|
Silicon Oil |
1000 CS, 1500 CS, 5000 CS |
S |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
20.1 Oxytocics |
||
|
Ergometrine Injection |
Injection (maleate) 0.5mg/mL (hydrogen maleate) in 1mL ampoule |
C |
|
Misoprostol |
Tablet 200mcg (rectal, sublingual) |
A |
|
Oxytocin Injection |
Injection 10 IU in 1mL ampoule |
A |
|
20.2 Antioxytocics (tocolytics) |
||
|
Dicyclomine |
Tablet 20mg; Injection |
B |
|
Nifedipine |
Immediate – release capsule: 10mg, 20mg |
B |
|
Salbutamol Tablet |
Tablet 4mg |
A |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
Iron Sucrose |
Injection 20mg/Ml |
D |
|
Intraperitoneal dialysis solution |
Parenteral solution (of appropriate composition) |
S |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
22.1 Medicines used in Psychotic Disorders |
||
|
Benzhexol |
Tablet 5mg |
C |
|
Chlorpromazine |
Injection (hydrochloride) 25mg/mL in 2mL ampoule; Tablet (hydrochloride) 25mg, 100mg |
A |
|
Donepezil |
Tablet 5mg, 10mg |
S |
|
Fluphenazine |
Injection 25mg/mL (decanoate) in 1mL ampoule |
C |
|
Haloperidol |
Injection 5mg/mL in 1mL ampoule; Tablet 1.5mg |
B |
|
Lorazepam |
Tablet 1mg, 2mg |
C |
|
Olanzapine |
Tablet 5mg; 10mg |
S |
|
Risperidone |
Tablet 1mg/2mg |
S |
|
Zuclopenthixol |
Injection 50mg/mL (Acetate) |
S |
|
22.2 Medicines Used in Mood Disorders |
||
|
22.2.1 Medicines used in Depressive disorders |
||
|
Amitriptyline |
Tablet (hydrochloride) 25mg |
A |
|
Citalopram |
Tablet 20mg |
D |
|
Fluoxetine |
Capsule 20mg |
S |
|
Imipramine |
Tablet 25 mg |
C |
|
Oxybutynin |
Tablet 5mg |
S |
|
22.2.2 Medicines in Bipolar Disorders |
||
|
Carbamazepine |
Tablet 100mg, 200mg |
A |
|
Lamotrigine |
Tablet 100mg, 200mg |
S |
|
Sodium Valproate |
Tablet 200mg, 500mg |
C |
|
22.3 Medicines Used for anxiety Disorders |
||
|
Diazepam |
Tablet 5mg |
C |
|
22.4 Medicines Used for Disorders due to Psychoactive Substance use |
||
|
Buprenorphine |
Sublingual Tablets2mg |
S |
|
Methadone |
Oral liquid: 5mg/5mL; 10mg/5mL |
C |
|
Naltrexone |
Tablet 50mg |
S |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
23.1 Anti-asthmatics |
||
|
Budesonide inhaler |
Inhalation 100mcg, 200mcg |
B |
|
Fluticasone propionate |
Nasal Spray 50mcg |
D |
|
Ipratropium Bromide Aerosol |
Inhalation (aerosol): 20 mcg/metered dose; Nebulizer 250- 500mcg |
S |
|
Montelucast |
Tablet 5mg; 10mg |
D |
|
Salbutamol |
Tablet (as sulfate) 4mg; syrup (as sulfate) 2mg/5mL; Inhalation (as sulfate) 0.1mg per dose (aerosol inhaler) |
A |
|
Nebulizer solution 2.5mg/mL; 5mg/mL; Injection 0.5mg/mL; img/mL |
B |
|
|
Salfolinl |
Inhalation 100mcg, 200mcg |
C |
|
Tiotropium |
Inhalation1.25mcg/actuation; 2.5mcg/actuation |
S (with special permit) |
|
23.2 Cough Preparations |
||
|
Cough syrup |
Containing expectorants/Antitussive Lictus |
A |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
Dextrose 5%; |
Dextrose 5%; 500mL, 1000mL |
A |
|
Dextrose 10%; |
Dextrose 10%; 500mL |
C |
|
Dextrose 25%, |
Dextrose 25%, 50mL, 100mL |
C |
|
Dextrose 50%, |
Dextrose 50%; 50mL, 100mL |
C |
|
Polystyrene sulfonate |
Solution containing calcium (or sodium) |
D |
|
Sodium bicarbonate |
Injection 5%, |
C |
|
Sodium lactate compound |
Sodium lactate compound (Ringer's solution) 500mL, 1000mL. |
A |
|
Sodium Chloride solution |
0.9% Sodium Chloride 500mL, 1000mL |
A |
|
Sodium Chloride solution |
3% Sodium Chloride 500mL, 1000mL |
C |
|
Sodium chloride+Dextrose |
Sodium chloride+Dextrose 0.9%+5%; 500mL, 1000mL |
B |
|
Potassium chloride Solution |
Potassium chloride Solution 7.4% 10mL Vial |
C |
|
Water for injection |
5mL, 10mL vial |
A |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
Ascorbic acid (Vitamin C) Tablet |
Ascorbic acid (Vitamin C) Tablet 100mg and 500mg |
A |
|
Calcium gluconate |
Injection 100mg/mL in 10mL ampoule |
A |
|
Calcium Carbonate |
Tablet 500mg |
S |
|
Calcium |
with vitamins |
C |
|
Calcium |
with amino acids |
C |
|
Ergocalciferol (vitamin D) |
Capsule 1.25mg (50, 000IU); Oral solution 0.25mg/mL (10,000IU/mL) |
C |
|
Glucosamine +Chondrotin sulphate |
Tablet |
S |
|
Iron |
with vitamins |
C |
|
Iron |
with amino acid |
C |
|
Nicotinamide (Vitamin B3) |
Tablet 50mg |
C |
|
Potassium chloride |
Tablet (slow release) 600mg; Injections |
C |
|
Pyridoxine (Vitamin B6) |
Tablet (hydrochloride) 25mg |
B |
|
Retinol (Vitamin A) Capsule |
Retinol (Vitamin A) Gelatin Capsule (with nipple to allow administration drop by drop) 50,000IU, 100,000IU 200, 000IU |
A |
|
Sodium Hyaluronate 1% |
Injection. 1% |
S |
|
Thiamine (Vitamin B1) |
Tablet (hydrochloride) 100mg |
C |
|
Thiamine (Vitamin B1) |
Injection (hydrochloride) 1000mg/mL in 1mL ampoule |
C |
|
Vitamin B complex |
Vitamin B complex Tablet BP (contains per Tablet: nicotinamide 15mg, iboflavin 1mg, thiamine 1mg) |
A |
|
Syrup (contains nicotinamide 15mg, riboflavin 1mg, thiamine 1mg/5mL) |
A |
|
|
Vitamin B complex |
Injection BP in 10mL vial (contains icotinamide 200mg, pantothenol 30mg, pyridoxine 20mg, riboflavine 20mg, thiamine 50mg per 1 mL) |
B |
|
Vitamin E |
Tablet/capsule alpha tocopherol acetate 500 mg/5 mL |
D |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
26.1 Ear Drops |
||
|
Betamethasone |
Ear drops; 0.1% w/v |
|
|
Boric acid |
Ear drop; 3% |
A |
|
Ciprofloxacin |
Ear drops; 0.3% |
C |
|
Clotrimazole |
Ear drops; 1% |
|
|
Chloramphenicol |
Ear drops; 5% w/v |
|
|
Dexamethasone + Neomycin |
Ear drops: 0.1% + 0.5% |
C |
|
Lidocaine + Beclometasone + Clotrimazole + Chloramphenicol |
Ear Drop | D |
|
26.2 Oral Antiseptics |
||
|
Chlorhexidine gluconate Solution |
Chlorhexidine gluconate Solution 0.1%; prepare from concentrated solution; gel |
B |
|
Potassium permanganate Solution |
Potassium permanganate Solution 1:4000; prepare from powder/crystals |
A |
|
26.3 Nasal Preparations |
||
|
Ephedrine |
Nasal drops 0.5% and 1% |
B |
|
Normal saline |
Nasal drop 0.9% |
A |
|
Mometasone |
Nasal spray 50 mcg/dose (as furoate) |
S |
|
Xylometazoline |
Nasal spray 0.05% |
S |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
Chlorhexidine + Cetrimide |
Solution concentrated containing chlorhexidine digluconate 1.5%+ 15% cetrimide |
A |
|
Chloroxylenol |
Solution 4.9% BP |
A |
|
Cresol saponated |
Solution 3% BP |
A |
|
Formaldehyde |
Solution 36 - 37% stabilized |
B |
|
Glutaraldehyde |
Activated solution 2% |
C |
|
Hydrogen peroxide |
Solution 3% |
A |
|
Hydrogen peroxide |
Solution 6% |
A |
|
Methylated spirit |
Solution 70% |
A |
|
Potassium permanganate |
Potassium permanganate Solution 1: 4000 |
A |
|
Povidone-Iodine |
Solution 10% |
A |
|
Sodium dichloroisocyanurate |
Tablet, 1.67g (equal to 1g available chlorine) |
A |
|
Name of drug |
Dosage forms and Strengths |
Level |
|
Sildenafil |
Tabet 50mg |
S |